Clinical trials: Covid19 Vaccine
Hospital Staff, Vaccined Againt COVID-19
Monitoring of the Post-vaccination Immune Response to COVID-19 Among Hospital Staff
Vaccination against COVID-19 is a major public health issue to control the epidemic and reduce the number of severe infections and deaths.
- Trial name
- COVIDIM (NCT04896788)
- Testing
- Monitoring of the immune response
- Where
- France
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- University Hospital, Clermont-Ferrand
Covid19, Kidney Transplantation
Monitoring of COVID-19 Vaccine Response in Organ Transplant Patients
Vaccination against SARS CoV-2 appears to be the best strategy today to control the COVID-19 pandemic. The first published studies with Pfizer, Moderna and Astra-Zeneca vaccines show very good vaccine protection in the general…
- Trial name
- COVATRANS (NCT04828460)
- Where
- France
- Volunteers
- 3,500 people
- Sponsor
- University Hospital, Strasbourg, France
Covid19
COVID-19: Safety and Immunogenicity of a Reduced Dose of the BioNTech/Pfizer BNT162b2 Vaccine
This is a randomized phase IV dose-optimization study evaluating the safety and immunogenicity of two doses of COVID-19 mRNA vaccines being authorized in the European Union since December 2020: Vaccine BNT162b2 (Comirnaty®…
- Trial name
- REDU-VAC (NCT04852861)
- Testing
- immunogenicity after first and second dose
- Where
- Belgium
- Volunteers
- 145 people, healthy volunteers welcome
- Sponsor
- Sciensano
Cancer, Covid-19
Effectiveness of mRNA Covid-19 Vaccines on Cancer Patients:Observational Study. (ANTICOV)
Based on recent data, COVID (COV) vaccination in cancer patients (pts) is strictly recommended. For oncologic pts,2 types of m-RNA vaccines have been approved: BNT162b2 (Pfizer, Biontech) and mRNA-1273 (Moderna, NIAID).
- Conditions
- Cancer, Covid-19, Vaccine Response
- Trial name
- ANTICOV (NCT04878796)
- Testing
- Serum collection, adverse events collection
- Where
- Italy
- Volunteers
- 300 people
- Sponsor
- Azienda Socio Sanitaria Territoriale di Cremona
Vaccine Uptake
Boosting COVID-19 Vaccination Uptake Using Wastewater Surveillance
Vaccinations are among the most successful and critical public health interventions. Despite the enormous protection that vaccines provide to public health, both delays and refusals of vaccines (vaccine hesitancy) are on the…
- Trial name
- NCT06698497
- Testing
- Communication Campaign
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Syracuse University
SARS-CoV2 Infection
COVAXIN in a Pediatric Cohort
The study is designed to evaluate the safety, reactogenicity and immunogenicity of three groups ages ≤18 - >12, ≤12 ->6, ≤ 6 - >2 years of healthy volunteers who receive two doses of the whole virion inactivated SARS-CoV-2 virus…
- Trial name
- COVAXIN-Peds (NCT04918797)
- Testing
- COVAXIN
- Where
- 7 sites in India
- Volunteers
- 525 people, healthy volunteers welcome
- Sponsor
- Bharat Biotech International Limited
COVID-19
Study of GRT-R910 COVID-19 Boost Vaccine in Healthy Volunteers
The primary objective was to assess the safety and tolerability of 2 different doses (10 or 30 µg) of GRT-R910 when administered as a boost in healthy adults previously vaccinated with the AstraZeneca, Janssen/Johnson and…
- Trial name
- NCT05148962
- Testing
- GRT-R910
- Where
- 3 sites in United Kingdom
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Gritstone bio, Inc.
Multiple Sclerosis, COVID-19
COVID-19 Vaccine Biomarker Study in Multiple Sclerosis
SARS CoV-2 is the virus responsible for the pandemic COVID-19, which has resulted in nearly five million deaths worldwide since its spread in the beginning of 2020.
- Trial name
- NCT05121662
- Where
- United States
- Volunteers
- 154 people, healthy volunteers welcome
- Sponsor
- Columbia University
SARS-CoV-2
A Phase I Clinical Trial to Evaluate the Safety, Tolerability, and Immunogenicity of SARS-CoV-2 Bivalent mRNA Vaccine (LVRNA021)
This trial is a phase I clinical trial of a SARS-CoV-2 Bivalent mRNA Vaccine (LVRNA021). The trial used a randomized, blinded, placebo-controlled design to evaluate the safety, tolerability, and preliminary immunogenicity of the…
- Trial name
- NCT05939596
- Testing
- SARS-CoV-2 Bivalent mRNA Vaccine, Saline
- Where
- China
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- AIM Vaccine Co., Ltd.
SARS-CoV-2 Vaccination
Adaptive Immune Response to COVID-19 Vaccination
AICOVI (Adaptive Immune Response to COVID-19 Vaccination) is a prospective clinical cohort study aiming at studying the kinetics of vaccine-specific antibody production after COVID-19 vaccination in health care workers.
- Trial name
- AICOVI (NCT04826770)
- Testing
- BNT162b2, AZD 1222, mRNA-1273
- Where
- Germany
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- University Medicine Greifswald
SARS-CoV-2 Virus Infection
COV-COMPARE Immunogenicity of Vaccine VLA2001 Compared to AZD1222
This is a multicentre, randomized, observer-blind, active-controlled, superiority, study in adults to compare the immunogenicity of VLA2001 to AZD1222 in terms of GMT of SARS-CoV-2-specific neutralising antibodies.
- Trial name
- COV-COMPARE (NCT04864561)
- Testing
- VLA2001, AZD1222, VLA2001 - adolescent part
- Where
- 31 sites in United Kingdom
- Volunteers
- 4,034 people, healthy volunteers welcome
- Sponsor
- Valneva Austria GmbH
COVID-19
Impact of New Variants and Vaccines on the Course of COVID-19
Novel coronavirus disease (COVID-19), caused by Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus, was first reported in December 2019 in Wuhan, China.
- Trial name
- COVID-19 (NCT05384886)
- Testing
- Polymerase chain reaction
- Where
- Turkey (Türkiye)
- Volunteers
- 15,967 people
- Sponsor
- Izmir Katip Celebi University
Allogenic Hematopoietic Cell Transplant, CAR-T Therapy
COVID-19 Vaccine in Patients After Allogeneic HCT, CAR-T Therapy and With Primary Immune Deficiency
The corona pandemic is a continuing global challenge due to Corona Virus 2019 (COVID-19). The purpose of the study is to confirm the accepted hypothesis from the recommendations of The European Society for Blood and Marrow…
- Conditions
- Allogenic Hematopoietic Cell Transplant, CAR-T Therapy, Primary Immunodeficiency
- Trial name
- NCT04724642
- Where
- Israel
- Volunteers
- 110 people
- Sponsor
- Tel-Aviv Sourasky Medical Center
COVID-19 Vaccine
A Study to Evaluate Immunogenicity and Safety of MVC-COV1901 Vaccine Compared With AZD1222
The primary objective of the study is to measure the anti-SARS-CoV-2 neutralizing antibody titres in adult participants, in particular elderly, so as to demonstrate immunogenic superiority of MVC-COV1901 to the active control…
- Trial name
- NCT05426343
- Testing
- MVC-COV1901, AZD1222
- Where
- Paraguay
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Medigen Vaccine Biologics Corp.
COVID-19
The Phase Ⅱ/Ⅲ Trial of LYB001
The study will be conducted in two phases using a randomized, double-blind, placebo-controlled design. A phase II trial will be initiated to assess the safety of LYB001 as booster shots, and then proceed to a phase III trial to…
- Trial name
- NCT05602558
- Testing
- LYB001
- Volunteers
- 18,000 people, healthy volunteers welcome
- Sponsor
- Yantai Patronus Biotech Co., Ltd.
COVID-19
Mix and Match of the COVID-19 Vaccine for Safety and Immunogenicity
The main goals of this study are to assess the immune response and safety of two different vaccines for first, second, third and fourth doses as well as for differing intervals between the first and second dose of two-dose…
- Trial name
- MOSAIC (NCT04894435)
- Testing
- mRNA-1273 SARS-CoV-2 vaccine, BNT162b2, ChAdOx1-S [recombinant]
- Where
- 8 sites in Canada
- Volunteers
- 669 people, healthy volunteers welcome
- Sponsor
- Canadian Immunization Research Network
COVID-19, Cancer
Immune Response to COVID-19 Vaccine in Immunotherapy (IO) and Non-IO Treated Cancer Patients
Evaluation of antibody response against SARS-CoV-2 vaccination in patients treated with IO-treatment, in comparison with antibody titers in patients treated with non-IO treatment.
- Trial name
- VIVACIOUS (NCT05062525)
- Where
- Canada
- Volunteers
- 53 people
- Sponsor
- University Health Network, Toronto
COVID-19 Pandemic
A PhaseⅡ Study to Evaluate the Safety & Immunogenicity of SARS-CoV-2 Alpha/Beta/Delta/Omicron Variants COVID-19 Vaccine
This study is a randomized, double-blind, placebo-controlled Phase II clinical trial to evaluate the safety and immunogenicity of SCTV01E in population of different ages who have been vaccinated against COVID-19.
- Trial name
- SCTV01E (NCT05652543)
- Testing
- SCTV01E
- Where
- 4 sites in China
- Volunteers
- 518 people, healthy volunteers welcome
- Sponsor
- Sinocelltech Ltd.
Coronavirus
Investigating a Vaccine Against COVID-19
A phase 2/3 study to determine the efficacy, safety and immunogenicity of the candidate Coronavirus Disease (COVID-19) vaccine ChAdOx1 nCoV-19 in healthy UK volunteers.
- Trial name
- NCT04400838
- Testing
- ChAdOx1 nCoV-19 (Abs 260), MenACWY vaccine, ChAdOx1 nCoV-19 (Abs 260) + 2.2x10^10vp (qPCR) boost
- Where
- 20 sites in United Kingdom
- Volunteers
- 10,811 people, healthy volunteers welcome
- Sponsor
- University of Oxford
COVID-19
A Clinical Trial on Sequential Immunization of Recombinant COVID-19 Vaccine (CHO Cell, NVSI-06-09) and Inactivated COVID-19 Vaccine (Vero Cell)
A total of 516 healthy subjects aged 18 years and above who have been vaccinated with 2 doses/3 doses of inactivated COVID-19 vaccine, will be enrolled, and randomly assigned to experimental group and control group in a 1:1…
- Trial name
- NCT05293548
- Testing
- Recombinant COVID-19 Vaccine (CHO cell，NVSI-06-09), Inactivated COVID-19 vaccine (Vero cells)
- Where
- United Arab Emirates
- Volunteers
- 516 people, healthy volunteers welcome
- Sponsor
- National Vaccine and Serum Institute, China
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.